Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-119

The primary out come required was (copied from the study)

"To determine Overall Treatment Success of rexlemestrocel-L alone or rexlemestrocel-L+HA through 24 months based on a composite responder analysis"

and from the result in bold it says

"Increased composite outcomes of reduction in pain together with improvement in function in those with CLBP of shorter duration than 68 months, the median for the study; however, the composite outcomes of pain and function did not reach statistical significance across the entire
study"

Other things really look encouraging, hopefully the webcast would shed some more light on overall results. fingers crossed...